Eli Lilly pushes back timeline for Alzheimer's drug application
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eli Lilly (LLY) PT Lowered to $305 at BMO Capital
February 4, 2022 6:55 AM ESTBMO Capital analyst Evan David Seigerman lowered the price target on Eli Lilly (NYSE: LLY) to $305.00 (from $310.00) while maintaining an Outperform rating.
The analyst commented, "Donanemab concerns overshadow a solid quarter and set up into 2022. Despite solid set of 4Q21 results and reiterated... More
Eli Lilly's (LLY) Fundamentals and Pipeline are Encouraging, Continue to Support Positive View - BMO Capital Markets
February 3, 2022 7:22 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $310.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 report.
The analyst quotes: "Beyond the financials, we are encouraged that key regulatory authorities accepted approval applications for tirzepatide as... More
Eli Lilly's (LLY) Earnings Outlook Continues to Look Favorable VS Peers, Reiterate Overweight - Cantor Fitzgerald
February 3, 2022 7:13 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $335.00 price target on Eli Lilly (NYSE: LLY), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales (beat versus FactSet for Trulicity, Taltz, Jardiance and Verzenio, among other... More
